The results of the migraine study will be delayed from the previously reported schedule
Biohit Oyj Stock Exchange Release 07.09.2018 at 15:00 local time (EET) The results of the migraine study will be delayed from the autumn 2018 which was reported in Biohit’s Half Year Financial Report (H1 2018). In Estonia, unexpected problems have been encountered in finding eligible patients for the study. Due to these challenges, the final results will not be available until the first reporting period of 2019. Additional information: CEO Semi Korpela, Biohit Oyj tel. +358 9 773 861 investor.relations@biohit.fi www.biohithealthcare.com Biohit Oyj in brief